Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of LCQ908 alone and with fenofibrate or Lovaza in severe hypertriglyceridemia
2012-000872-40Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pradigastat in hypertriglyceridemia and familial chylomicronemia syndrome (FCS) (6 arms), sponsored by Novartis. Primary endpoint: Primary triglyceride change at 6 weeks. Started Aug 2012; status: terminated.
02
Drugs
pradigastat
03
Conditions
hypertriglyceridemiafamilial chylomicronemia syndrome (FCS)
Beyond the preview
Go deeper on 2012-000872-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000872-40.